top of page
ATXA Therapeutics in Berlin for the EIC Innovators’ Summit 2018
DUBLIN, IRELAND – September 10, 2018 – From 10-11 September 2018, the European Innovation Council (EIC) will host more than 600 top SMEs,...
Sep 10, 2018
ATXA Therapeutics Secures €2.5m EU Funding for Novel Pulmonary Arterial Hypertension Therapy
DUBLIN, IRELAND – May 15, 2018 – ATXA Therapeutics Limited, an Irish company developing novel therapeutic drugs for the treatment of...
May 15, 2018
Presidential Reception celebrating Female Entrepreneurship, Innovation, Creativity & Sustainable
DUBLIN, IRELAND – May 10, 2018 – Founder & Chief Scientific Officer of ATXA Therapeutics, Prof. Therese Kinsella, attended a reception...
May 10, 2018
ATXA Therapeutics to Attend the 2018 Medtech Strategist Innovation Summit
DUBLIN, IRELAND – April 3, 2018 – ATXA Therapeutics Limited Founder and Chief Scientific Officer, Prof. Therese Kinsella, PhD, MRIA, will...
Apr 3, 2018
FDA Grants Orphan Drug Designation to ATXA’s NTP42 for the Treatment of PAH
DUBLIN, IRELAND – March 8, 2018 – ATXA Therapeutics Limited, an early-stage Irish biopharmaceutical company focused on clinical...
Mar 8, 2018
ATXA Therapeutics receives EMA Orphan Drug Designation for NTP42 for the treatment of Pulmonary Arte
DUBLIN, IRELAND – February 23, 2018 – ATXA Therapeutics Limited, an early-stage Irish biopharmaceutical company focused on clinical...
Feb 23, 2018
ATXA Therapeutics to Present at the 2018 Biotech and Money / Medtech and Money World Congress Showca
DUBLIN, IRELAND – February 2, 2018 – ATXA Therapeutics Limited, an early-stage Irish biopharmaceutical company focused on clinical...
Feb 2, 2018
COMPANY UPDATES
bottom of page